Rakha, N., Ibrahim, T., Abdalla, N., Ali, E., Said, R. (2022). Patched Homolog Gene (PTCHI) As a Reliable Marker for Predicting Imatinib Response in Chronic Phase Chronic Myeloid Leukemia Patients in Correlation with Early Response to First Line of Treatment Imatinib. test, 89(1), 5241-5247. doi: 10.21608/ejhm.2022.262203
Nahed Moawad Rakha; Tamer Mohamed Ibrahim; Nour Elhoda Hussein Abdalla; Esraa Shaaban Ali; Rasha Magdy Said. "Patched Homolog Gene (PTCHI) As a Reliable Marker for Predicting Imatinib Response in Chronic Phase Chronic Myeloid Leukemia Patients in Correlation with Early Response to First Line of Treatment Imatinib". test, 89, 1, 2022, 5241-5247. doi: 10.21608/ejhm.2022.262203
Rakha, N., Ibrahim, T., Abdalla, N., Ali, E., Said, R. (2022). 'Patched Homolog Gene (PTCHI) As a Reliable Marker for Predicting Imatinib Response in Chronic Phase Chronic Myeloid Leukemia Patients in Correlation with Early Response to First Line of Treatment Imatinib', test, 89(1), pp. 5241-5247. doi: 10.21608/ejhm.2022.262203
Rakha, N., Ibrahim, T., Abdalla, N., Ali, E., Said, R. Patched Homolog Gene (PTCHI) As a Reliable Marker for Predicting Imatinib Response in Chronic Phase Chronic Myeloid Leukemia Patients in Correlation with Early Response to First Line of Treatment Imatinib. test, 2022; 89(1): 5241-5247. doi: 10.21608/ejhm.2022.262203

Patched Homolog Gene (PTCHI) As a Reliable Marker for Predicting Imatinib Response in Chronic Phase Chronic Myeloid Leukemia Patients in Correlation with Early Response to First Line of Treatment Imatinib

The Egyptian Journal of Hospital Medicine
Article 173, Volume 89, Issue 1, October 2022, Pages 5241-5247    PDF (323.57 K)
Document Type: Original Article
DOI: 10.21608/ejhm.2022.262203
Authors
Nahed Moawad Rakha; Tamer Mohamed Ibrahim; Nour Elhoda Hussein Abdalla; Esraa Shaaban Ali; Rasha Magdy Said
Clinical Hematology Unit, Internal Medicine Department, Ain shams university, Cairo Egypt
Abstract
Background:Chronic myeloid leukaemia (CML) is a clonal disease of a hematopoietic stem cell. The incidence of this disease is about 15% of leukemias and may be present at any age. The presence of the Philadelphia (Ph) chromosome confirms the diagnosis of CML. The expression of the Patched homolog 1 gene (PTCH1) has been proposed as a prognostic marker of imatinib response in chronic phase chronic myeloid leukaemia (CP-CML) patients.
Aim: This study aimed to measure the level of PTCH1 protein in newly diagnosed CP-CML and to find correlation between its level in those patients and response to first line of treatment, imatinib and other prognostic factors.
Patients and Methods: Our study enrolled 50 patients of newly diagnosed CP-CML. We have measured the level of PTCH1 protein initially once the patient diagnosed and after 6 months of treatment with imatinib by ELISA test.
Results: There was highly significant difference between initial PTCH1 level and its level after 6 months of imatinib treatment (P=0.000). The level of PTCH 1 was correlated significantly with the molecular response both at the beginning of treatment with imatinib and six months later. (P=0.002), (p=0.001) respectively.
Conclusion: To the best of our knowledge that we are the first to report on PTCH1 protein as a new diagnostic and prognostic marker in CP-CML patients.
 
Keywords
Chronic Phase; Patched Homolog Gene (PTCHI); Chronic Myeloid Leukemia; ELISA; Imatinib
Statistics
Article View: 160
PDF Download: 295